

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement and Non-factor Therapy

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years.

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. January 11, 2017 /MarketersMedia/ -- Hemophilia is a rare disease affecting more than 400,000 people worldwide. Hemophilia A is four times as common as hemophilia B, and more than half of patients with hemophilia A have a severe form of hemophilia. Males have a much higher chance of developing hemophilia because they only receive one copy of the X chromosome from their mother.

The mainstay of treatment for hemophilia is to replace the missing factor VIII or factor IX, produced using plasma-derived or recombinant methods. Some patients develop inhibitors to factor VIII or factor IX treatment and need a bypassing agent, such as factor VIIa, to resolve bleeds. Patients of hemophilia A or B often require lifelong treatment to prevent and control bleeding episodes, and this therefore represents a lucrative market opportunity.

Complete Report Available at:
<http://www.reportsweb.com/hemophilia-a-and-b-therapeutics-in-asia-pacific-markets-to-2022> .

The current marketed products landscape comprises replacement factor therapies, such as recombinant therapies and new long-acting recombinant products. The current pipeline shows strong promise, as it shows a gradual shift from short-acting recombinant factor VIII or factor IX to long-acting recombinant factor VIII, and from factor replacement therapies to non-factor therapies. Nevertheless, significant unmet need remains for products that can avoid the development of inhibitors in patients with hemophilia.

Though late-stage pipeline for treatment of hemophilia seems promising, the main market restraint is likely to be low penetration of new long-acting recombinant therapies in India and China, owing to their high expected prices.

Get Sample of the Report at: <http://www.reportsweb.com/inquiry&RW0001488236/sample> .

Report Scope

The Hemophilia A and B Asia-Pacific market will be valued at \$699.1m and \$112.9m respectively in 2022, growing from \$444.9m and \$76.3m in 2015, at compound annual growth rates of 6.7% and 5.8%.

- How will non-factor therapies contribute to the growth?
- What will be the impact of the new long-acting recombinant factor VIII and recombinant factor IX products in the hemophilia A and B market sales?

The pipeline contains a range of molecule types and molecular targets, including both those that are well established in hemophilia A and B, and novel targeted therapies.

Inquire about Report at: <http://www.reportsweb.com/inquiry&RW0001488236/buying> .

Table of Contents

1.1 List of Tables 8

1.2 List of Figures 9

2 Introduction 11
3 Marketed Products 21
4 Pipeline Analysis 42
5 Clinical Trial Analysis 63
6 Multi-scenario Forecast 73
7 Drivers and Barriers 93
8 Deals and Strategic Consolidations 95
9 Appendix 106
9.3 Bibliography 114
9.4 Abbreviations 122
9.5 Research Methodology 122
9.5.1 Secondary Research 122
9.5.2 Marketed Product Profiles 123
9.5.3 Late-Stage Pipeline Candidates 123
9.5.4 Comparative Efficacy and Safety Heatmap for Marketed and Pipeline Products 123
9.5.5 Product Competitiveness Framework 123
9.5.6 Pipeline Analysis 123
9.5.7 Forecasting Model 124
9.5.8 Deals Data Analysis 125
9.6 Contact Us 126
9.7 Disclaimer 126

Purchase this Report at: <http://www.reportsweb.com/buy&RW0001488236/buy/4995> .

For more information, please visit <http://www.reportsweb.com/hemophilia-a-and-b-therapeutics-in-asia-pacific-markets-to-2022>Contact Info:Name: Sameer JoshiEmail: sales@reportsweb.comOrganization: ReportsWebAddress: Pune, India.Phone: +1-646-491-9876Source:

<http://marketersmedia.com/hemophilia-a-and-b-therapeutics-in-asia-pacific-markets-to-2022-by-increasing-treatment-receiving-pool-launch-of-long-acting-replacement-and-non-factor-therapy/160516>Release ID: 160516

Contact Information

For more information visit <http://> (<http://>)

Keywords

You can read this press release online [here](#)